PCM
LGND icon

Penn Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Penn Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.7M Buy
100,337
+4,881
+5% +$1.15M 2.01% 4
2026
Q1 		$19.1M Sell
95,456
-3,392
-3% -$671K 1.48% 14
2025
Q4 		$18.7M Sell
98,848
-8,434
-8% -$1.62M 1.49% 12
2025
Q3 		$19M Sell
107,282
-13,102
-11% -$1.95M 1.46% 11
2025
Q2 		$13.7M Sell
120,384
-455
-0.4% -$48.6K 1.18% 41
2025
Q1 		$12.7M Buy
120,839
+16,409
+16% +$1.86M 1.24% 37
2024
Q4 		$11.2M Buy
104,430
+4,212
+4% +$476K 1.1% 45
2024
Q3 		$10M Buy
+100,218
New +$10.1M 0.92% 51

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penn Capital Management's LGND Position: Q2 2026 in Review

Penn Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 5.1% in Q2 2026, buying an estimated $1.15M and bringing the position to 100,337 shares worth $31.7M. The position accounts for 2.01% of the portfolio, ranked #4.

Penn Capital Management first reported a position in LGND in Q3 2024 and has held it in 8 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Penn Capital Management held 100,337 shares of Ligand Pharmaceuticals worth $31.7M as of Q2 2026.
  • Penn Capital Management bought 4,881 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.15M.
  • Ligand Pharmaceuticals made up 2.01% of Penn Capital Management's portfolio in Q2 2026, its #4 holding.
  • Penn Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.